Sumitomo Mitsui Trust Group
SYRS icon

Sumitomo Mitsui Trust Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-516,629
Closed -$38.6M – 1217
2021
Q1 		$38.6M Buy
516,629
+78,430
+18% +$8.15M 0.02% 608
2020
Q4 		$47.5M Buy
438,199
+19,964
+5% +$1.82M 0.03% 553
2020
Q3 		$37M Sell
418,235
-54,242
-11% -$6.16M 0.02% 574
2020
Q2 		$50.4M Sell
472,477
-20,044
-4% -$1.8M 0.04% 494
2020
Q1 		$29.2M Sell
492,521
-4,945
-1% -$335K 0.03% 568
2019
Q4 		$34.4M Buy
497,466
+34,089
+7% +$2.07M 0.03% 585
2019
Q3 		$48.1M Buy
463,377
+304,472
+192% +$28.8M 0.04% 459
2019
Q2 		$14.7M Buy
158,905
+90,457
+132% +$6.3M 0.01% 697
2019
Q1 		$6.26M Buy
+68,448
New +$4.77M 0.01% 708

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Sumitomo Mitsui Trust Group's SYRS Position: Q2 2021 in Review

Sumitomo Mitsui Trust Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 516,629 shares — an estimated $38.6M sold.

Sumitomo Mitsui Trust Group first reported a position in SYRS in Q1 2019 and held it in 9 quarters. The position peaked at $50.4M in Q2 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • Sumitomo Mitsui Trust Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 516,629 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $38.6M.
  • Sumitomo Mitsui Trust Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 9 quarters.
  • Sumitomo Mitsui Trust Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $50.4M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2021, filed 2 Aug 2021.